← Back to Search

Tau Imaging with F-18 AV 1451 for Progressive Supranuclear Palsy

N/A
Recruiting
Led By Keith Josephs, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must meet criteria for possible or probable Progressive Supranuclear Palsy. To fulfill criteria for possible PSP, subjects must have a gradually progressive disorder with either vertical (upward or downward) supranuclear palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of disease onset. To fulfill criteria for probable PSP, subjects must have vertical (upward or downward gaze) supranuclear palsy and prominent postural instability with falls in the first year of disease onset.
Be older than 18 years old
Must not have
Subjects will be excluded if they meet criteria for another neurodegenerative disease (including corticobasal syndrome, frontotemporal dementia, primary progressive aphasia, Alzheimer's disease, multiple system atrophy and Parkinson's disease) or do not have the symptoms necessary to fulfill inclusion criteria for possible PSP
Subjects will be excluded from the study if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will study tau burden in the brains of PSP patients to learn more about the disease.

Who is the study for?
This trial is for adults over 35 with Progressive Supranuclear Palsy (PSP) symptoms and a diagnosis of possible or probable PSP. Participants need an informant to provide additional information about their functioning. Exclusions include pregnancy, other neurodegenerative diseases, conditions that mimic PSP symptoms, certain genetic conditions increasing cancer risk, contraindications to MRI, severe claustrophobia, and unstable medical conditions.
What is being tested?
The study tests the imaging agent F-18 AV 1451 to measure tau protein accumulation in the brain of patients with PSP. It aims to understand the overall burden of tau in these patients using advanced imaging techniques.
What are the potential side effects?
As this trial involves an imaging procedure rather than a drug treatment, side effects are minimal but may include discomfort from lying still during scanning and potential allergic reactions to the tracer.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Progressive Supranuclear Palsy.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any other neurodegenerative diseases besides possible PSP.
Select...
I do not have genetic conditions like Cowden, Lynch syndrome, or Down's syndrome.
Select...
I do not have illnesses like brain injury, encephalitis, strokes, or developmental syndromes.
Select...
I am not pregnant or breastfeeding.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Tau PET Scan, F-18 AV 1451Experimental Treatment1 Intervention
All subjects will received a Tau PET scan.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,360 Previous Clinical Trials
3,065,609 Total Patients Enrolled
Keith Josephs, MDPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
47 Total Patients Enrolled
Jennifer Whitwell, PhDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
77 Total Patients Enrolled

Media Library

F-18 AV 1451 Clinical Trial Eligibility Overview. Trial Name: NCT02605785 — N/A
Progressive Supranuclear Palsy Research Study Groups: Tau PET Scan, F-18 AV 1451
Progressive Supranuclear Palsy Clinical Trial 2023: F-18 AV 1451 Highlights & Side Effects. Trial Name: NCT02605785 — N/A
F-18 AV 1451 2023 Treatment Timeline for Medical Study. Trial Name: NCT02605785 — N/A
~28 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top